This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, J. Articles by Brown, J. M. Search for Related Content PubMed PubMed Citation Articles by Wang, J. Articles by Brown, J. M.

Repair of DNA and Chromosome Breaks in Cells Exposed to SR 4233 under Hypoxia or to Ionizing Radiation¹

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305

3-Amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) is a bioreductive anticancer drug which has a high selective toxicity to hypoxic cells. We have characterized the DNA and chromosome damage in wild-type Chinese hamster ovary (CHO) cells and mutant XR-1 cells after exposure to SR 4233 under hypoxia and compared it to the damage produced by ionizing radiation (-rays). Using the technique of pulsed field gel electrophoresis, we found that the kinetics of rejoining of DNA double-strand breaks in CHO cells after treatment with SR 4233 was concentration dependent, varying from 95% (<50 µM) to 10% (200 µM) by 24 h. This contrasted with the dose-independent kinetics exhibited in cells after -ray exposure. XR-1 cells were deficient in rejoining double-strand breaks produced by either SR 4233 or -rays. XR-1 cells were 2-fold more sensitive than wild-type CHO cells to SR 4233 but were 10-fold more sensitive than CHO to -rays. These results suggested that DNA double-strand breaks are involved in hypoxic cell killing by SR 4233, but the specific type of lesion produced is not identical with that causing cell killing by -rays. To further investigate this, we measured chromosome breaks in CHO cells by premature chromosome condensation after equitoxic doses of SR 4233 under hypoxia and -rays. SR 4233 produced lower initial but similar final (after 6 h of repair) numbers of chromosome breaks compared to -rays at equitoxic doses. These results suggest that, at low doses, chromosome breaks can entirely account for hypoxic cell killing by SR 4233 and that chromosome breaks produced by SR 4233 are more damaging and/or more difficult to repair than those produced by -rays.

¹ Supported by USPHS Grant 5R37CA15201 from the National Cancer Institute. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

² To whom requests for reprints should be addressed.

Received 2/21/92. Accepted 6/ 5/92.

This article has been cited by other articles:

				J. W. Evans, S. B. Chernikova, L. A. Kachnic, J. P. Banath, O. Sordet, Y. M. Delahoussaye, A. Treszezamsky, B. H. Chon, Z. Feng, Y. Gu, et al. Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells Cancer Res., January 1, 2008; 68(1): 257 - 265. [Abstract] [Full Text] [PDF]

				A. Azqueta, G. Pachon, M. Cascante, E. E. Creppy, and A. Lopez de Cerain DNA damage induced by a quinoxaline 1,4-di-N-oxide derivative (hypoxic selective agent) in Caco-2 cells evaluated by the comet assay Mutagenesis, May 1, 2005; 20(3): 165 - 171. [Abstract] [Full Text] [PDF]

				V. M. Aquino, S. D. Weitman, N. J. Winick, S. Blaney, W. L. Furman, J. L. Kepner, P. Bonate, M. Krailo, W. Qu, and M. Bernstein Phase I Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors: A Pediatric Oncology Group Study J. Clin. Oncol., April 15, 2004; 22(8): 1413 - 1419. [Abstract] [Full Text] [PDF]

				B. G. Siim, F. B. Pruijn, J. R. Sturman, A. Hogg, M. P. Hay, J. M. Brown, and W. R. Wilson Selective Potentiation of the Hypoxic Cytotoxicity of Tirapazamine by Its 1-N-Oxide Metabolite SR 4317 Cancer Res., January 15, 2004; 64(2): 736 - 742. [Abstract] [Full Text] [PDF]

				E. C. Chinje, R. L. Cowen, J. Feng, S. P. Sharma, N. S. Wind, A. L. Harris, and I. J. Stratford Non-Nuclear Localized Human NOSII Enhances the Bioactivation and Toxicity of Tirapazamine (SR4233) in Vitro Mol. Pharmacol., June 1, 2003; 63(6): 1248 - 1255. [Abstract] [Full Text] [PDF]

				K. B. Peters and J. M. Brown Tirapazamine: A Hypoxia-activated Topoisomerase II Poison Cancer Res., September 15, 2002; 62(18): 5248 - 5253. [Abstract] [Full Text] [PDF]

				K. B. Peters, H. Wang, J. M. Brown, and G. Iliakis Inhibition of DNA Replication by Tirapazamine Cancer Res., July 1, 2001; 61(14): 5425 - 5431. [Abstract] [Full Text] [PDF]

				B. G. Wouters, Y. M. Delahoussaye, J. W. Evans, G. W. Birrell, M. J. Dorie, J. Wang, D. MacDermed, R. K. Chiu, and J. M. Brown Mitochondrial Dysfunction after Aerobic Exposure to the Hypoxic Cytotoxin Tirapazamine Cancer Res., January 1, 2001; 61(1): 145 - 152. [Abstract] [Full Text]

				J. M. Brown The Hypoxic Cell: A Target for Selective Cancer Therapy--Eighteenth Bruce F. Cain Memorial Award Lecture Cancer Res., December 1, 1999; 59(23): 5863 - 5870. [Abstract] [Full Text] [PDF]